Lilly seeks US FDA approval for oral once-daily RA drug, baricitinib

Lilly seeks US FDA approval for oral once-daily RA drug, baricitinib

… biopharmaceutical company, announced that Lilly has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid

(Visited 3 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.